Annual Oral Cancer Screening Program

ViziLite Plus with TBlue™ is an oral lesion identification and marking system that is used as an adjunct to the conventional head and neck examination. It is comprised of a chemiluminescent light source (ViziLite) to improve the identification of lesions and a blue phenothiazine dye to mark those lesions identified by ViziLite. ViziLitePlus with TBlueTM is designed to be used in a patient population at increased risk for oral cancer.

Lumenoscopy™ -  Examination of the Oral Cavity with ViziLite

 In clinical trials involving 13,000 female patients, abnormal squamous epithelium in the cervical complex appears distinctly white after washing the cervix with a dilute acetic acid solution and viewed under chemiluminescent light (Speculite®).  Similarly, examination of the oral cavity under chemiluminescent light (ViziLite) after rinsing with a dilute acetic acid solution, abnormal squamous epithelium tissue will appear distinctly white. Lumenoscopy™ has demonstrated in numerous studies to improve the ability to visualize mucosal lesions and initially identify clinically suspicious lesions. 

ViziLite Lumenoscopy™

 TBlue™ Oral Lesion Marking System

TBlueTM is a patented, pharmaceutical-grade toluidine blue-based metachromatic dye.  It is used to further evaluate and closely monitor changes in ViziLite-identified lesions.  It has been proposed that living cells will differentially accumulate toluidine blue based on parameters related to metabolic activity.  TBlueTM , packaged in an easy to use 3-swab system, provides the deep blue staining that allows ViziLite-identified lesions to be seen clearly under normal light.